Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Age-related macular degeneration - Cost-of-illness issues
Autore:
ONeill, C; Jamison, J; McCulloch, D; Smith, D;
Indirizzi:
Univ Ulster, Sch Publ Policy Econ & Law, Jordanstown BT37 0QB, Newtownabbey, North Ireland Univ Ulster Jordanstown Newtownabbey North Ireland BT37 0QB North Ireland Queens Univ Belfast, Hlth & Social Care Res Unit, Belfast, Antrim, North Ireland Queens Univ Belfast Belfast Antrim North Ireland , Antrim, North Ireland Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England Univ York York N Yorkshire England YO1 5DD YO1 5DD, N Yorkshire, England
Titolo Testata:
DRUGS & AGING
fascicolo: 4, volume: 18, anno: 2001,
pagine: 233 - 241
SICI:
1170-229X(2001)18:4<233:AMD-CI>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BEAVER DAM EYE; DIABETIC-RETINOPATHY; VISUAL IMPAIRMENT; RADIATION-THERAPY; LOW VISION; PREVALENCE; BLINDNESS; REHABILITATION; MACULOPATHY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
68
Recensione:
Indirizzi per estratti:
Indirizzo: O'Neill, C Univ Ulster, Sch Publ Policy Econ & Law, Jordanstown BT37 0QB, Newtownabbey, North Ireland Univ Ulster Jordanstown Newtownabbey North Ireland BT37 0QB nd
Citazione:
C. O'Neill et al., "Age-related macular degeneration - Cost-of-illness issues", DRUG AGING, 18(4), 2001, pp. 233-241

Abstract

Macular degeneration refers to the breakdown of cells in the centre of theretina. Some degeneration is an inevitable consequence of the aging process; however, when this is associated with loss of sight in the central part of the field of vision an underlying pathology is considered present. Amongthose aged 55 years, the prevalence of the disease in the US was estimatedat 1% rising to approximately 15% among those aged 80 years. Other studiesestimate the prevalence of the disease to be higher and to be increasing. The main effect of the disease is to reduce the ability of the individual to engage in everyday activities that require clear central vision. It may also be associated with elevated risks of depression and increased levels of dependency. Currently there is no effective treatment for the majority ofpatients. For a minority (< 10%) laser photocoagulation therapy may be effective in reducing the risk of severe vision loss. Another treatment, photodynamic therapy, is in development and many others are at an experimental stage. This review sought to establish current knowledge on the cost of illness associated with age-related macular degeneration (ARMD). A search of the literature, together with direct communication with researchers in related fields and patient support/advocacy groups, was undertaken to ascertain current knowledge on the cost of illness of ARMD. While literature on the disease is extensive and literature on treatments is emerging, no substantive information on direct or indirect costs was found although evidence that loss of earnings may occur is beginning to emerge. Some information does exist on cost of illness in diabetic retinopathy, adisease with similarities to ARMD, though even for this disease gaps in knowledge are apparent and wide variations exhibited. Given current knowledge, it is not possible to report on the cost of illness for ARMD with confidence. The lack of information on the cost of illness in ARMD presents difficulties for researchers and policy makers in assessing the cost effectiveness of the existing treatment, as well as new treatments as they become available. Given developments in treatments and the increasing prevalence of thedisease, it is important that cost-of-illness information is gathered for ARMD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 10:24:03